{"id":"W4397007360","doi":"10.1016/j.esmoop.2024.103115","title":"127P Atezolizumab (A) + pertuzumab + trastuzumab (PH) + chemotherapy (CT) in HER2-positive early breast cancer (HER2+ eBC): Final results of the phase III IMpassion050 trial","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Pertuzumab; Atezolizumab; Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004509129,0.0004115532,0.000733898,0.0001514405,0.0001139006,0.0003247859,0.0003064756,0.0004104463,0.01021034],"category_scores_gemma":[0.0003813759,0.0001499359,0.0005766249,0.0002037681,0.0001950196,0.0002168316,0.0001871871,0.0009035846,0.001235373],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003007964,"about_ca_system_score_gemma":0.0003759095,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003265167,"about_ca_topic_score_gemma":0.0009686651,"domain_scores_codex":[0.9998505,0.00008297172,0.000009456679,0.00001753893,0.00002026799,0.00001926107],"domain_scores_gemma":[0.9998586,0.00004532187,0.00003078375,0.000009442697,0.00000935698,0.00004644672],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6497934,0.007046884,0.003575217,0.002304717,0.001399327,0.0001768658,0.00006365079,0.001212972,0.02667059,0.0003917525,0.02230427,0.2850603],"study_design_scores_gemma":[0.6977673,0.249105,0.02460667,0.0002367358,0.001337681,0.0006786904,0.00004215656,0.001496381,0.007010098,0.0003943989,0.01730273,0.00002218304],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.963206,0.008464118,0.001354654,0.0008848775,0.0002696867,0.002347062,0.00957617,0.000220012,0.01367738],"genre_scores_gemma":[0.9696867,0.005627342,0.001659468,0.0009843499,0.0001822223,0.002478992,0.008573693,0.00004292715,0.01076434],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01021034,"threshold_uncertainty_score":0.03415698,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0517048107338275,"score_gpt":0.4141104975485573,"score_spread":0.3624056868147298,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}